Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of guselkumab for moderate-to-severe hidradenitis suppurativa completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED | Results posted: 2021-06-14